Drug, Healthcare and Patient Safety (Sep 2019)
Safety and tolerability of macitentan in the management of pulmonary arterial hypertension: an update
Abstract
Alexandra K Wong,1 Richard N Channick2 1Division of Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA 02114, USA; 2Division of Pulmonary and Critical Care, University of California Los Angeles Medical Center, Los Angeles, CA 90095, USACorrespondence: Alexandra K WongDivision of Pulmonary and Critical Care, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USATel +1 617 724 9674Fax +1 617 726 6878Email [email protected]: Macitentan is a medication in the endothelin receptor antagonist class, approved for treatment of pulmonary arterial hypertension in 2013 based on the results of the pivotal SERAPHIN Trial (Study with an Endothelin Receptor Antagonist in Pulmonary arterial Hypertension to Improve cliNical outcome). Macitentan was shown in initial trials to reduce the likelihood of a morbidity/mortality event. Real-world use of this medication additionally reveals a reduced risk of hospitalizations related to pulmonary arterial hypertension, improved health-related quality of life scores, potential clinical utility in other conditions (such as chronic thromboembolic pulmonary hypertension and pulmonary hypertension related to congenital heart disease), and has a similar safety profile as demonstrated in initial trials.Keywords: macitentan, pulmonary arterial hypertension, safety, tolerability, efficacy
